Literature DB >> 7490742

Genomic organization and chromosomal location of the human dsRNA adenosine deaminase gene: the enzyme for glutamate-activated ion channel RNA editing.

Y Wang1, Y Zeng, J M Murray, K Nishikura.   

Abstract

The structure of the human gene encoding the double-stranded RNA (dsRNA) adenosine deaminase (DRADA) was characterized. This nuclear localized enzyme is involved in the RNA editing required for the expression of certain subtypes of glutamate-gated ion channel subunits. The DRADA gene span 30 kb pairs and harbors 15 exons. The transcription of the DRADA gene driven by the putative promoter region, which contains no typical TATA or CCAAT box-like sequences, is initiated at multiple sites, 164 to 216 nucleotides upstream of the translation initiation codon. The three dsRNA binding motifs (DRBM), 70 amino acid residues long, are each encoded by two exons plus an intervening sequence that interrupts the motif at the identical amino acid position. This finding is consistent with the notion that the dsRNA binding domains may be composed of two separate functional subdomains. Fluorescent in situ hybridization localized the DRADA gene on the long arm chromosome 1, region q21. The gene structure and sequence information reported in this study will facilitate the investigation of involvement of DRADA in hereditary diseases that may be the result of malfunction of glutamate-gated ion channels.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7490742     DOI: 10.1006/jmbi.1995.0610

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  19 in total

Review 1.  Activity regulation of adenosine deaminases acting on RNA (ADARs).

Authors:  Cesare Orlandi; Alessandro Barbon; Sergio Barlati
Journal:  Mol Neurobiol       Date:  2011-11-20       Impact factor: 5.590

Review 2.  Adenosine deaminases acting on RNA, RNA editing, and interferon action.

Authors:  Cyril X George; Zhenji Gan; Yong Liu; Charles E Samuel
Journal:  J Interferon Cytokine Res       Date:  2010-12-23       Impact factor: 2.607

Review 3.  ADARs: viruses and innate immunity.

Authors:  Charles E Samuel
Journal:  Curr Top Microbiol Immunol       Date:  2012       Impact factor: 4.291

Review 4.  Adenosine deaminase acting on RNA (ADAR1), a suppressor of double-stranded RNA-triggered innate immune responses.

Authors:  Charles E Samuel
Journal:  J Biol Chem       Date:  2019-02-01       Impact factor: 5.157

5.  Human RNA-specific adenosine deaminase ADAR1 transcripts possess alternative exon 1 structures that initiate from different promoters, one constitutively active and the other interferon inducible.

Authors:  C X George; C E Samuel
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-13       Impact factor: 11.205

Review 6.  An RNA editor, adenosine deaminase acting on double-stranded RNA (ADAR1).

Authors:  Cyril X George; Lijo John; Charles E Samuel
Journal:  J Interferon Cytokine Res       Date:  2014-06       Impact factor: 2.607

7.  Hyperediting of human T-cell leukemia virus type 2 and simian T-cell leukemia virus type 3 by the dsRNA adenosine deaminase ADAR-1.

Authors:  Nga Ling Ko; Emmanuel Birlouez; Simon Wain-Hobson; Renaud Mahieux; Jean-Pierre Vartanian
Journal:  J Gen Virol       Date:  2012-09-19       Impact factor: 3.891

Review 8.  Adenosine deaminases acting on RNA (ADARs) are both antiviral and proviral.

Authors:  Charles E Samuel
Journal:  Virology       Date:  2011-01-05       Impact factor: 3.616

9.  Mutations of the RNA-specific adenosine deaminase gene (DSRAD) are involved in dyschromatosis symmetrica hereditaria.

Authors:  Yoshinori Miyamura; Tamio Suzuki; Michihiro Kono; Katsuhiko Inagaki; Shiro Ito; Noriyuki Suzuki; Yasushi Tomita
Journal:  Am J Hum Genet       Date:  2003-08-11       Impact factor: 11.025

10.  Editing of the GLuR-B ion channel RNA in vitro by recombinant double-stranded RNA adenosine deaminase.

Authors:  G A Dabiri; F Lai; R A Drakas; K Nishikura
Journal:  EMBO J       Date:  1996-01-02       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.